News articles about National Health Investors (NYSE:NHI) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. National Health Investors earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the real estate investment trust an impact score of 46.8212351693604 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern’s rankings:
National Health Investors (NYSE:NHI) opened at $67.33 on Wednesday. The stock has a market capitalization of $2,722.85, a PE ratio of 17.40, a price-to-earnings-growth ratio of 3.38 and a beta of 0.48. The company has a debt-to-equity ratio of 0.87, a current ratio of 13.85 and a quick ratio of 13.85. National Health Investors has a fifty-two week low of $62.71 and a fifty-two week high of $81.60.
The business also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Stockholders of record on Friday, March 30th will be paid a $1.00 dividend. This is a boost from National Health Investors’s previous quarterly dividend of $0.95. The ex-dividend date is Wednesday, March 28th. This represents a $4.00 annualized dividend and a dividend yield of 5.94%. National Health Investors’s dividend payout ratio is presently 98.19%.
A number of equities analysts have issued reports on NHI shares. Stephens set a $79.00 target price on National Health Investors and gave the stock a “buy” rating in a report on Friday, January 12th. Zacks Investment Research cut National Health Investors from a “buy” rating to a “hold” rating in a report on Friday, November 17th. KeyCorp reaffirmed an “underweight” rating on shares of National Health Investors in a report on Tuesday, December 19th. Stifel Nicolaus set a $76.00 target price on National Health Investors and gave the stock a “buy” rating in a report on Saturday, February 17th. Finally, SunTrust Banks set a $75.00 target price on National Health Investors and gave the stock a “hold” rating in a report on Monday, January 22nd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. National Health Investors presently has a consensus rating of “Hold” and a consensus price target of $77.75.
In related news, CEO D. Eric Mendelsohn purchased 2,000 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was bought at an average price of $65.47 per share, with a total value of $130,940.00. Following the completion of the purchase, the chief executive officer now owns 10,580 shares in the company, valued at approximately $692,672.60. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP John L. Spaid purchased 500 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $64.95 per share, with a total value of $32,475.00. Following the purchase, the vice president now owns 971 shares of the company’s stock, valued at approximately $63,066.45. The disclosure for this purchase can be found here. In the last three months, insiders bought 2,812 shares of company stock valued at $183,910. Insiders own 5.19% of the company’s stock.
About National Health Investors
National Health Investors, Inc is a self-managed real estate investment trust (REIT) specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. The Company is engaged in the business of owning and financing healthcare properties.